MGNX

Macrogenics Inc

2.40

Oct 30 • 3:59 PM ET +0.02 (0.84%)

2.40

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: XNCR STRO CTMX ZYME PYXS CGEN ALXO IPHA ADAG INBX

| Held by: VTI IWM VXF VTWO IWO FESM VFMO IWC VTWG IWN

Scroll to Statements

Index	RUT
Market Cap	152.88M
Enterprise Value	177.82M
Income	-14.59M
Sales	167.67M
Book/sh	0.67
Cash/sh	2.72
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	293
IPO	Oct 10, 2013

P/E	-
Forward P/E	-
PEG	-
P/S	0.91
P/B	3.56
P/C	0.88
P/FCF	-
EV/EBITDA	-
EV/Sales	1.06
Quick Ratio	2.96
Current Ratio	2.96
Debt/Eq	4.62
LT Debt/Eq	4.51
Option/Short	Yes / Yes

EPS (ttm)	-0.23
EPS next Y	-1.64
EPS next Q	-0.32
EPS this Y	-49.27%
EPS next Y	6.89%
EPS next 5Y	-20.19%
EPS past 3/5Y	15.37% 13.74%
Sales past 3/5Y	-0.54% 7.35%
EPS Y/Y TTM	59.94%
Sales Y/Y TTM	1.32%
EPS Q/Q	153.45%
Sales Q/Q	47.62%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	497.95% -44.48%

Insider Own	3.54%
Insider Trans	-1.36%
Inst Own	79.40%
Inst Trans	10.20%
ROA	-35.12%
ROE	-231.86%
ROIC	-6.18%
Gross Margin	77.86%
Oper. Margin	-24.30%
Profit Margin	-8.70%
SMA20	-24.40%
SMA50	-34.95%
SMA200	-29.77%
Trades

Shs Outstand	63.65M
Shs Float	61.44M
Short Float	8.24%
Short Ratio	7.64
Short Interest	5.06M
52W High	5.08 -52.76%
52W Low	1.29 86.05%
Volatility	12.14% 10.63%
ATR (14)	0.29
RSI (14)	31.75
Beta	1.28
Rel Volume	1.79
Avg Volume	662.50K
Volume	1,182,990

Perf Week	6.67%
Perf Month	-33.33%
Perf Quarter	-37.17%
Perf Half Y	-23.32%
Perf YTD	49.07%
Perf Year	50.47%
Perf 3Y	-53.49%
Perf 5Y	-87.71%
Perf 10Y	-89.90%
Recom	2.17
Target Price	8.00
Prev Close	2.38
Price	2.40
Change %	0.84%

Consensus

Buy

Avg. Price Target

$8.00

Implied Upside

+233.3%

Analysts12incl. previous ratings

Rating Distribution3 Buy · 9 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Apr 10, 2026	Upgrade	RB. Riley Securities	Neutral → Buy	$9	+275.0%
Sep 17, 2025	Resumed	BBarclays	Overweight	$3	+25.0%
Nov 07, 2024	Downgrade	JJMP Securities	Mkt Outperform → Mkt Perform
Aug 01, 2024	Downgrade	BBTIG Research	Buy → Neutral
Jul 31, 2024	Downgrade	GGuggenheim	Buy → Neutral
Jul 31, 2024	Downgrade	RB. Riley Securities	Buy → Neutral	$18 → $5	+108.3%
May 10, 2024	Downgrade	TTD Cowen	Buy → Hold
May 10, 2024	Downgrade	SStifel	Buy → Hold	$29 → $7	+191.7%
May 10, 2024	Downgrade	BBMO Capital Markets	Outperform → Market Perform	$24 → $8	+233.3%
Apr 26, 2024	Initiated	RB. Riley Securities	Buy	$25	+941.7%
Apr 09, 2024	Upgrade	TTD Cowen	Hold → Buy
Mar 04, 2024	Reiterated	BBTIG Research	Buy	$12 → $24	+900.0%
Feb 14, 2024	Downgrade	HH.C. Wainwright	Buy → Neutral	$12 → $14	+483.3%
Dec 20, 2023	Upgrade	CCitigroup	Neutral → Buy	$7 → $13	+441.7%
Nov 07, 2023	Upgrade	GGuggenheim	Neutral → Buy	$12	+400.0%
Mar 17, 2023	Downgrade	GGuggenheim	Buy → Neutral
Nov 22, 2022	Downgrade	CCowen	Outperform → Market Perform
Nov 14, 2022	Upgrade	BBMO Capital Markets	Market Perform → Outperform	$5.70 → $16	+566.7%
Jul 18, 2022	Downgrade	SSMBC Nikko	Outperform → Neutral	$5	+108.3%
Jul 11, 2022	Downgrade	BBMO Capital Markets	Outperform → Market Perform	$31 → $4	+66.7%

Oct-26-26 07:06AM	MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer (GlobeNewswire)
Oct-23-26 09:15AM	MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN (GlobeNewswire) -38.02%
Oct-15-26 04:05PM	MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors (GlobeNewswire)
Sep-09-26 04:05PM	MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-13-26 05:05PM	MacroGenics: Q2 Earnings Snapshot (Associated Press)
04:05PM	Loading…
04:05PM	MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position (GlobeNewswire)
Aug-11-26 04:05PM	MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program (GlobeNewswire)
Jul-23-26 04:01PM	MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026 (GlobeNewswire) -6.74% -7.73%
Jul-02-26 06:40PM	VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone (Exec Edge)
09:25AM	MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals (GlobeNewswire)
Jun-22-26 04:43PM	MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval (GlobeNewswire) +10.90%
May-28-26 06:33PM	Akari Therapeutics Highlights 1st ASCO Abstract Acceptance (IPO-Edge.com)
12:53PM	VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC (Exec Edge)
May-14-26 04:01PM	MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum (GlobeNewswire) +20.58%
May-13-26 04:26PM	MacroGenics: Q1 Earnings Snapshot (Associated Press)
04:01PM	Loading…
04:01PM	MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation (GlobeNewswire)
May-12-26 11:08AM	GMP Manufacturing Sale Gives MacroGenics Additional Non-Dilutive Capital for Pipeline Development (MGNX) (InvestorsHub) +19.32%
May-11-26 05:20PM	MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals (GlobeNewswire)
May-04-26 07:30AM	MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ Royalty Purchase Agreement (GlobeNewswire)
Apr-08-26 04:30PM	FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study (GlobeNewswire)
Mar-09-26 05:15PM	MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.83% +45.34%
04:23PM	MacroGenics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures (GlobeNewswire)
Feb-26-26 06:00PM	BioLife Solutions, Inc. (BLFS) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
05:30PM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-24-26 06:16AM	Why Is MacroGenics Stock Sinking Tuesday? (Benzinga)
Feb-23-26 06:14PM	MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial (GlobeNewswire)
Jan-13-26 09:19AM	Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes (Zacks)
Jan-05-26 10:26AM	FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children (Zacks) +6.83%
Nov-25-25 04:05PM	MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
05:15PM	Loading…
Nov-12-25 05:15PM	MacroGenics (MGNX) Q3 Earnings and Revenues Surpass Estimates (Zacks) +8.84%
04:07PM	MacroGenics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress (GlobeNewswire)
Nov-10-25 09:55AM	MacroGenics (MGNX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-06-25 04:30PM	MacroGenics to Participate in the Stifel 2025 Healthcare Conference (GlobeNewswire) -5.56%
Oct-30-25 05:30PM	Stryker (SYK) Q3 Earnings and Revenues Beat Estimates (Zacks) -5.62%
Sep-02-25 04:30PM	MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +9.77%
Aug-14-25 05:15PM	MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:10PM	MacroGenics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities (GlobeNewswire)
Aug-13-25 04:01PM	MacroGenics Appoints Eric Risser as President and Chief Executive Officer (GlobeNewswire) +12.93%
08:50AM	OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Jul-31-25 07:25AM	SNDL Inc. (SNDL) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-29-25 05:10PM	AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.39%
Jun-10-25 07:00AM	MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ Royalty Purchase Agreement (GlobeNewswire) +8.54%
Jun-03-25 04:30PM	MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (GlobeNewswire) +8.63%
May-22-25 09:36AM	Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies (Zacks) +6.04%
May-21-25 11:37AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks) -5.10%
May-13-25 05:15PM	MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:11PM	MacroGenics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results (GlobeNewswire)
May-12-25 09:46AM	What To Expect From Macrogenics Inc (MGNX) Q1 2025 Earnings (GuruFocus.com) +11.19%
07:15AM	Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 07:40AM	Owens & Minor (OMI) Q1 Earnings Top Estimates (Zacks)
May-07-25 05:40PM	Biote Corp. (BTMD) Q1 Earnings and Revenues Surpass Estimates (Zacks)
May-06-25 04:30PM	MacroGenics Announces Date of First Quarter 2025 Financial Results (GlobeNewswire) -10.37%
May-01-25 04:30PM	MacroGenics to Participate in Upcoming Investor Conference (GlobeNewswire)
Apr-17-25 08:52AM	4 Medical Product Stocks to Buy From a Challenging Industry (Zacks) +6.78%
Apr-03-25 09:35AM	MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.74%
Mar-21-25 02:19PM	MacroGenics axes ADC drug following Phase II failure in prostate cancer (Clinical Trials Arena)
12:05PM	Macrogenics Inc (MGNX) Q4 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
09:29AM	Q4 2024 MacroGenics Inc Earnings Call (Thomson Reuters StreetEvents)
03:05AM	Macrogenics Inc (MGNX) Q4 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses (GuruFocus.com)
Mar-20-25 08:15PM	MacroGenics (MGNX) Q4 2024 Earnings Call Transcript (Motley Fool)
07:09PM	MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:00PM	MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:50PM	MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:02PM	MacroGenics Provides Update on Corporate Progress and 2024 Financial Results (GlobeNewswire)
10:00AM	Here are the major earnings after the close today (SeekingAlpha)
Mar-19-25 05:35PM	MacroGenics FY 2024 Earnings Preview (SeekingAlpha) +6.34%
05:15PM	Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-06-25 07:30AM	MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call (GlobeNewswire)
Feb-27-25 07:30AM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Dec-02-24 04:30PM	MacroGenics to Participate in Upcoming Investor Conference (GlobeNewswire) -6.78%
Nov-06-24 04:30PM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.14% +6.44%
08:51AM	Q3 2024 MacroGenics Inc Earnings Call (Thomson Reuters StreetEvents)
02:25AM	Macrogenics Inc (MGNX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Developments (GuruFocus.com)
Nov-05-24 10:15PM	MacroGenics (MGNX) Q3 2024 Earnings Call Transcript (Motley Fool)
08:00PM	Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings (Zacks)
07:30PM	MacroGenics (MGNX) Beats Q3 Earnings and Revenue Estimates (Zacks)
06:26PM	MacroGenics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-04-24 07:13AM	Earnings To Watch: Macrogenics Inc (MGNX) Reports Q3 2024 Result (GuruFocus.com)
Oct-30-24 07:30AM	MacroGenics Announces Leadership Transition (GlobeNewswire)
Oct-29-24 04:30PM	MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call (GlobeNewswire) -5.11%
Oct-23-24 08:41AM	TerSera acquires global rights to MacroGenics' MARGENZA for breast cancer treatment (Pharmaceutical Business Review)
Oct-22-24 07:30AM	MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA (Business Wire)
Sep-24-24 05:45AM	MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX (PR Newswire)
Sep-23-24 11:05AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile) -6.71%
Sep-20-24 05:06AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Sep-19-24 01:29PM	MacroGenics, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights MGNX (GlobeNewswire)
Sep-17-24 08:30AM	MacroGenics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MGNX (PR Newswire)
05:45AM	Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX (PR Newswire)
Sep-15-24 03:00AM	MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 (GlobeNewswire)
Sep-13-24 08:34AM	Do Options Traders Know Something About MacroGenics (MGNX) Stock We Don't? (Zacks)
Sep-11-24 08:30AM	MacroGenics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MGNX (PR Newswire)
Sep-08-24 07:10PM	MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024 (GlobeNewswire)
Sep-04-24 03:29PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Sep-03-24 05:45AM	Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX (PR Newswire) -6.55%
Sep-02-24 02:05PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Karen Ferrante	Former Director	Oct 22 '26	Proposed Sale	3.60	22,000	79,204		Oct 22 04:16 PM
Bonvini Ezio	Sr VP, Research & CSO	Oct 06 '26	Option Exercise	2.60	8,000	20,800	193,799	Oct 07 04:22 PM
Thomas Spitznagel	Former Officer	Sep 21 '26	Proposed Sale	4.14	15,811	65,530		Sep 21 04:10 PM
Peters Jeffrey Stuart	Senior VP, GC, and Secretary	Aug 19 '26	Sale	4.15	31,105	129,086	0	Aug 20 06:19 PM
Jeffrey Peters	Officer	Aug 19 '26	Proposed Sale	4.15	31,105	129,145		Aug 19 05:20 PM
Bonvini Ezio	Sr VP, Research & CSO	Aug 17 '26	Option Exercise	2.60	40,000	104,000	185,799	Aug 18 04:19 PM
Jay Siegel	Former Director	Aug 17 '26	Proposed Sale	4.18	42,080	175,695		Aug 17 05:36 PM
Jay Siegel	Former Director	Aug 03 '26	Proposed Sale	3.75	34,916	130,935		Aug 03 04:30 PM
Thomas Spitznagel	Former Officer	Jul 13 '26	Proposed Sale	4.44	17,000	75,529		Jul 13 09:26 PM
Koenig Scott	Director	Feb 15 '26	Option Exercise	0.00	21,165	0	867,240	Feb 17 06:22 PM

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

CEOMr. Eric Blasius Risser

Senior VP & CFOMr. James Karrels

Senior VP of Research & Chief Scientific OfficerDr. Ezio Bonvini M.D.

Vice President of Technical OperationsDr. Araba Lamouse-Smith Ph.D.

Senior VPMr. Jeffrey Stuart Peters J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MGNX

Macrogenics Inc

Upgrade your Finviz experience